<< Poll finds more confidence about paying for health care; young adults most supportive of reform | Clinical Healthcare Enterprise Framework to help healthcare HR for effective talent management >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Cumberland Pharmaceuticals to discuss its recently approved FDA product at the UBS Conference

Published on September 1, 2009 at 4:15 AM · No Comments

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer A.J. Kazimi will present at the UBS Global Life Sciences Conference in New York at 11:00 a.m. Eastern Time on Monday, September 21, 2009. Mr. Kazimi will provide an update on the Company and its Caldolor product, which Cumberland is preparing to launch following its recent approval by the Food and Drug Administration.

The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section on Cumberland Pharmaceuticals' website at www.cumberlandpharma.com. Shortly following the live webcast, a replay will be available and archived for 30 days.

Source: http://www.cumberlandpharma.com

Posted in: Pharmaceutical News

Tags: , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading